2012 -- H 7824 | |
======= | |
LC01879 | |
======= | |
STATE OF RHODE ISLAND | |
| |
IN GENERAL ASSEMBLY | |
| |
JANUARY SESSION, A.D. 2012 | |
| |
____________ | |
| |
A N A C T | |
RELATING TO STATE AFFAIRS AND GOVERNMENT -- MEDICAID GENERIC DRUG | |
SAVINGS | |
|
      |
|
      |
     Introduced By: Representatives Williams, and Hull | |
     Date Introduced: February 28, 2012 | |
     Referred To: House Health, Education & Welfare | |
It is enacted by the General Assembly as follows: | |
1-1 |
     SECTION 1. Title 42 of the General Laws entitled "STATE AFFAIRS AND |
1-2 |
GOVERNMENT" is hereby amended by adding thereto the following chapter: |
1-3 |
     CHAPTER 14.7 |
1-4 |
THE RHODE ISLAND MEDICAID GENERIC DRUG COMPETITION AND SAVINGS ACT |
1-5 |
     42-14.7-1. Short title. – This act shall be known and may be cited as the “Medicaid |
1-6 |
Generic Drug Competition And Savings Act.” |
1-7 |
     42-14.7-2. Definitions. – As used in this chapter: |
1-8 |
     (1) “Medicaid” means the Medicaid program, established in title XIX of the social |
1-9 |
security act, which provides medical benefits to groups of low-income people. In this chapter, |
1-10 |
“Medicaid” refers to the state Medicaid program managed by the state of Rhode Island. |
1-11 |
     (2) “Generics” or “generic drugs” means copies of brand name drugs that are no longer |
1-12 |
protected by patents. Generics are drugs that contain the same active ingredient, are identical in |
1-13 |
strength, dosage form, and route of administration as the brand name innovator drug and has the |
1-14 |
same indications, dosing, and labeling and provides the same efficacy and safety profile to |
1-15 |
patients as the brand name innovator drug. |
1-16 |
     (3) “Generic manufacturers” means manufacturers, both domestic and international, that |
1-17 |
manufacture generic drugs and distribute those generics throughout the state through various |
1-18 |
distribution systems. |
2-19 |
     (4) “Competitive bidding” means a transparent procurement method in which bids from |
2-20 |
generic manufacturers are invited by openly advertising the scope, specifications, and terms and |
2-21 |
conditions of the proposed contract as well as the criteria by which the bids will be evaluated. The |
2-22 |
objective of competitive bidding is obtaining goods at the lowest prices by stimulating |
2-23 |
competition, and by preventing favoritism. |
2-24 |
     42-14.7-3. Findings. – The general assembly hereby finds and declares that: |
2-25 |
     (1) With every prescription filled with a generic, the consumer receives the same |
2-26 |
medicine as the brand name, with the same quality and same result, but at a much lower cost. |
2-27 |
     (2) For more than twenty-five (25) years, America’s generic pharmaceutical industry has |
2-28 |
been providing the food and drug administration (FDA) approved generic versions of brand name |
2-29 |
medicines at a savings to consumers of thirty percent (30%) to as much as eighty percent (80%). |
2-30 |
     (3) Millions of Medicaid recipients nationwide are using generics to treat a variety of |
2-31 |
medical conditions, including infection, heart disease and cancer. Generics are rigorously tested |
2-32 |
by the FDA and must prove that they are the same medicine with the same active ingredient, |
2-33 |
strength and dosage as their brand name counterpart. Today, there are thousands of generic drugs |
2-34 |
available and all are manufactured and inspected under the same strict quality guidelines as a |
2-35 |
brand. |
2-36 |
     (4) For most brand name products there are multiple generics available and these generics |
2-37 |
can vary greatly in prices. |
2-38 |
     (5) While the state Medicaid program has encouraged the use of generics drugs by |
2-39 |
Medicaid recipients, it has not taken advantage of the savings that could be generated by taking |
2-40 |
advantage of the competition among generic manufacturers which vary greatly in their pricing of |
2-41 |
generic drugs. |
2-42 |
     42-14.7-4. Competitive bidding. – The Rhode Island department of human services shall |
2-43 |
require all generic manufacturers whose products are to be provided to Medicaid recipients to |
2-44 |
engage in a competitive bidding process created by the department of health to ensure that it is |
2-45 |
providing Medicaid recipients with quality generic products at a competitively bid cost. |
2-46 |
     SECTION 2. This act shall take effect upon passage. |
      | |
======= | |
LC01879 | |
======== | |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO STATE AFFAIRS AND GOVERNMENT -- MEDICAID GENERIC DRUG | |
SAVINGS | |
*** | |
3-1 |
     This act would require manufacturers of generic drugs provided to Medicaid recipients to |
3-2 |
engage in a competitive bidding process. |
3-3 |
     This act would take effect upon passage. |
      | |
======= | |
LC01879 | |
======= |